Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL30801293 | 0.86 | KDR (0.41) | DAPK3JAK2CSF1RRETPRKACA | |
| Hydrochloric Acid SCHEMBL30066525 | 0.86 | KDR (0.41) | DAPK3JAK2CSF1RRETPRKACA | |
| SCHEMBL31496664 | 0.86 | KDR (0.41) | KDM4EALDH1A1HPGDHSD17B10DAPK3 | |
| SCHEMBL31687184 | 0.86 | KDR (0.41) | KDM4EALDH1A1HPGDHSD17B10DAPK3 | |
| SCHEMBL29649189 | 0.86 | KDR (0.41) | KDM4EALDH1A1HPGDHSD17B10DAPK3 | |
| SCHEMBL400139 | 0.83 | — | — | |
| Hydrazine SCHEMBL6036676 | 0.82 | DRD4 (0.40) | KDM4EDAPK3JAK2CSF1RRET | |
| SCHEMBL30994991 | 0.77 | TRIM24 (0.39) | ALDH1A1DAPK3JAK2CSF1RRET | |
| SCHEMBL31665891 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| EP-2646025-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| EP-2600863-A2 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-06-12 | — | — | EP | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| EP-2571501-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-03-27 | — | — | EP | disclosed |
| EP-2531191-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-12-12 | — | — | EP | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| WO-2012072782-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012016980-A2 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011095584-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | KDM4E 4501/4885ALDH1A1 1524/4885HPGD 1041/4885 |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | KDM4E 4055/4885ALDH1A1 388/4885HPGD 1280/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | KDM4E 4767/4885ALDH1A1 960/4885HPGD 2901/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | KDM4E 3826/4885ALDH1A1 1184/4885HPGD 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.